ZA200601181B - Method of treating viral infections - Google Patents
Method of treating viral infections Download PDFInfo
- Publication number
- ZA200601181B ZA200601181B ZA200601181A ZA200601181A ZA200601181B ZA 200601181 B ZA200601181 B ZA 200601181B ZA 200601181 A ZA200601181 A ZA 200601181A ZA 200601181 A ZA200601181 A ZA 200601181A ZA 200601181 B ZA200601181 B ZA 200601181B
- Authority
- ZA
- South Africa
- Prior art keywords
- ribavirin
- dose
- interferon
- day
- administered
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 64
- 208000036142 Viral infection Diseases 0.000 title claims description 22
- 230000009385 viral infection Effects 0.000 title claims description 22
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 85
- 229960000329 ribavirin Drugs 0.000 claims description 83
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 83
- 102000014150 Interferons Human genes 0.000 claims description 52
- 108010050904 Interferons Proteins 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 49
- 229940079322 interferon Drugs 0.000 claims description 48
- 238000009472 formulation Methods 0.000 claims description 47
- 210000004185 liver Anatomy 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 38
- 230000009885 systemic effect Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 208000005176 Hepatitis C Diseases 0.000 claims description 17
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 15
- 108010047761 Interferon-alpha Proteins 0.000 claims description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims description 14
- 230000036765 blood level Effects 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 13
- 229960003507 interferon alfa-2b Drugs 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims description 12
- 229950000038 interferon alfa Drugs 0.000 claims description 11
- 239000003223 protective agent Substances 0.000 claims description 11
- 230000003442 weekly effect Effects 0.000 claims description 10
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 8
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 230000003836 peripheral circulation Effects 0.000 claims description 7
- 210000003240 portal vein Anatomy 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- 230000003389 potentiating effect Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 claims description 5
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 4
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 2
- 230000003628 erosive effect Effects 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 239000008185 minitablet Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- -1 ribavirin ester Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 35
- 230000000694 effects Effects 0.000 description 19
- 230000001225 therapeutic effect Effects 0.000 description 12
- 230000004087 circulation Effects 0.000 description 11
- 238000002648 combination therapy Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 230000001839 systemic circulation Effects 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 8
- 230000029142 excretion Effects 0.000 description 7
- 241000711549 Hepacivirus C Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002440 hepatic effect Effects 0.000 description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229960004166 diltiazem Drugs 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003521 interferon alfa-2a Drugs 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003253 viricidal effect Effects 0.000 description 2
- 230000009265 virologic response Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- OSKSVLBJJXQUPI-UHFFFAOYSA-N 2h-triazole-4-carboxamide Chemical compound NC(=O)C1=CNN=N1 OSKSVLBJJXQUPI-UHFFFAOYSA-N 0.000 description 1
- GTODOEDLCNTSLG-UHFFFAOYSA-N 2h-triazole-4-carboxylic acid Chemical class OC(=O)C1=CNN=N1 GTODOEDLCNTSLG-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010055511 interferon alfa-2c Proteins 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 229940109242 interferon alfa-n3 Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49482803P | 2003-08-13 | 2003-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601181B true ZA200601181B (en) | 2007-04-25 |
Family
ID=34193246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601181A ZA200601181B (en) | 2003-08-13 | 2004-08-03 | Method of treating viral infections |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070202078A1 (https=) |
| EP (1) | EP1660116A4 (https=) |
| JP (1) | JP2007501806A (https=) |
| CN (1) | CN1835765A (https=) |
| AR (1) | AR045263A1 (https=) |
| AU (1) | AU2004264255A1 (https=) |
| BR (1) | BRPI0413474A (https=) |
| CA (1) | CA2535451A1 (https=) |
| CL (1) | CL2004002030A1 (https=) |
| IL (1) | IL173630A0 (https=) |
| NO (1) | NO20060651L (https=) |
| NZ (1) | NZ545159A (https=) |
| RU (1) | RU2371195C2 (https=) |
| WO (1) | WO2005016370A1 (https=) |
| ZA (1) | ZA200601181B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| CA2480826C (fr) | 2002-04-09 | 2012-02-07 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| CN1847256B (zh) * | 2005-04-13 | 2011-06-15 | 长春华普生物技术有限公司 | 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用 |
| WO2006131790A2 (en) * | 2005-06-09 | 2006-12-14 | Flamel Technologies | Oral ribavirin pharmaceutical composition |
| WO2009031918A1 (ru) * | 2007-09-05 | 2009-03-12 | Shatunovsky Nikolai Evgenievic | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с |
| WO2009046369A2 (en) * | 2007-10-05 | 2009-04-09 | Medtronic, Inc. | Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c |
| PE20110343A1 (es) * | 2008-09-17 | 2011-06-25 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina |
| US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| US20130295052A1 (en) | 2010-11-19 | 2013-11-07 | Manu Chaudhary | Novel conjugates for targeted drug delivery |
| RU2665638C1 (ru) * | 2017-05-24 | 2018-09-03 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3222259A (en) * | 1963-10-25 | 1965-12-07 | Ethyl Corp | Flare stack with a liquid seal |
| JPS5439143Y2 (https=) * | 1976-04-16 | 1979-11-20 | ||
| US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| DK1136075T3 (da) * | 1997-09-21 | 2003-04-28 | Schering Corp | Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| CA2331823A1 (en) * | 1998-05-15 | 1999-11-25 | Schering Corporation | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| JP2002527522A (ja) * | 1998-10-16 | 2002-08-27 | シェリング・コーポレーション | 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法 |
| AR021876A1 (es) * | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
| US6962717B1 (en) * | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
| AU4463300A (en) * | 1999-04-19 | 2000-11-02 | Schering Corporation | Hcv combination therapy, containing ribavirin in association with antioxidants |
| WO2001081359A1 (en) * | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| EP1326594A2 (en) * | 2000-10-18 | 2003-07-16 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| PL369129A1 (en) * | 2001-09-28 | 2005-04-18 | Intermune, Inc. | Method for treating hepatitis c virus infection in treatment failure patients |
| CA2372987A1 (en) * | 2001-12-11 | 2003-06-11 | Thomas R. Wiseman | Method of disposal of liquid from gas wells |
-
2004
- 2004-08-03 JP JP2006522842A patent/JP2007501806A/ja active Pending
- 2004-08-03 US US10/568,176 patent/US20070202078A1/en not_active Abandoned
- 2004-08-03 ZA ZA200601181A patent/ZA200601181B/en unknown
- 2004-08-03 EP EP04737647A patent/EP1660116A4/en not_active Ceased
- 2004-08-03 CN CNA200480023166XA patent/CN1835765A/zh active Pending
- 2004-08-03 AU AU2004264255A patent/AU2004264255A1/en not_active Abandoned
- 2004-08-03 NZ NZ545159A patent/NZ545159A/en unknown
- 2004-08-03 RU RU2006107566/15A patent/RU2371195C2/ru not_active IP Right Cessation
- 2004-08-03 WO PCT/AU2004/001031 patent/WO2005016370A1/en not_active Ceased
- 2004-08-03 BR BRPI0413474-5A patent/BRPI0413474A/pt not_active IP Right Cessation
- 2004-08-03 CA CA002535451A patent/CA2535451A1/en not_active Abandoned
- 2004-08-09 CL CL200402030A patent/CL2004002030A1/es unknown
- 2004-08-12 AR ARP040102894A patent/AR045263A1/es unknown
-
2006
- 2006-02-09 NO NO20060651A patent/NO20060651L/no not_active Application Discontinuation
- 2006-02-09 IL IL173630A patent/IL173630A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006107566A (ru) | 2007-09-20 |
| NZ545159A (en) | 2009-03-31 |
| AR045263A1 (es) | 2005-10-19 |
| JP2007501806A (ja) | 2007-02-01 |
| CN1835765A (zh) | 2006-09-20 |
| BRPI0413474A (pt) | 2006-10-17 |
| US20070202078A1 (en) | 2007-08-30 |
| CA2535451A1 (en) | 2005-02-24 |
| RU2371195C2 (ru) | 2009-10-27 |
| IL173630A0 (en) | 2006-07-05 |
| CL2004002030A1 (es) | 2005-06-03 |
| WO2005016370A1 (en) | 2005-02-24 |
| EP1660116A4 (en) | 2008-04-30 |
| EP1660116A1 (en) | 2006-05-31 |
| NO20060651L (no) | 2006-05-02 |
| AU2004264255A1 (en) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6299872B1 (en) | Combination therapy for chronic hepatitis c infection | |
| US20050112093A1 (en) | Combination therapy for HCV infection | |
| CA2425522A1 (en) | Ribavirin-pegylated interferon alfa hcv combination therapy | |
| US20070202078A1 (en) | Method Of Treating Viral Infections | |
| KR101174966B1 (ko) | 철이 발병에 관여하는 간질환의 치료 | |
| US20110165119A1 (en) | Telaprevir dosing regimen | |
| EP2593105A1 (en) | Palatable pharmaceutical composition comprising vx-950 | |
| JP2007501806A5 (https=) | ||
| US20130225483A1 (en) | New Treatments of Hepatitis C Virus Infection | |
| MXPA06001695A (en) | Method of treating viral infections | |
| Chandra et al. | 561 Safety and pharmacokinetics of the now nucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects | |
| KR20140011379A (ko) | 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료 | |
| HK1008811A (en) | Combination therapy for chronic hepatitis c infection | |
| NZ615539B2 (en) | Treatment of hepatitis c virus infection with alisporivir |